Floatz Rating
CC46/100
Confidence
Indicative
Sponsor
iN Therapeutics Co., Ltd.
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06218784CT.gov A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients. | — | Recruiting | — | — | — |
NCT05496205CT.gov A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Osteoarthritis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| in1011-n17 (this asset) | iN Therapeutics Co., Ltd. | P1 | CC · 46 |
| Naltrexone | Brigham and Women's Hospital | P4 | BBB |
| Buprenorphine | Mundipharma Pte Ltd. | P4 | BBB |
| Fentanyl | Janssen Pharmaceutica | P4 | BBB |
| Oxycodone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P4 | BBB |
| Liraglutide | Henrik Gudbergsen | P4 | BBB |
| Duloxetine | The Catholic University of Korea | P4 | BBB |
| Tapentadol | Janssen Scientific Affairs, LLC | P4 | BB |
| Triamcinolone Hexacetonide | Kastamonu University | P4 | BB |
+39 more in the Osteoarthritis cohort
Other indications for in1011-n17
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Postherpetic Neuralgia | — | P1 | CC · 47 |
| Neuralgia | — | P1 | CC · 42 |
| Chronic Pain Syndrome | — | P1 | CC · 42 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. in1011-n17 in Osteoarthritis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/in1011-n17-osteoarthritis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →